This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

6.4 Key Companies 43

6.4.1 3SBio 43

6.4.2 Shanghai CP Guojian Pharmaceutical Co. Ltd. 45

6.4.3 Biotech Pharma 46

7 Biosimilars in Emerging Economies – Other Emerging Economies 48

7.1 Brazil 48

7.1.1 Biosimilars Regulatory Framework and Approval Process 48

7.1.2 Biosimilars Coverage and Availability at Reduced Cost 48

7.1.3 Biosimilars Market Opportunity 48

7.1.4 Major Challenge 49

7.2 Russia 49

7.3 Mexico 50

7.4 Turkey 50

7.4.1 Biosimilar Guidelines in Turkey 50

7.4.2 Risk Management Plan 51

7.4.3 New Pharmacovigilance Legislation 51

7.4.4 Actavis and Bioton Collaborate for Insulin 52

7.5 Argentina 52

7.5.1 Major Challenge 52

7.6 South Africa 53

7.6.1 Guidelines for Similar Biological Medicines 53

7.6.2 Genius Biotherapeutics 53

7.6.3 Major Challenges 54

7.7 Venezuela 54

7.8 Vietnam 55

7.8.1 Innogene Kalbiotech 55

7.8.2 Major Challenge 56

7.9 Thailand 56

7.9.1 Major Challenges 57

8 Biosimilars in Emerging Economies – Pipeline Analysis 58

8.1 Introduction 58

8.2 R&D Pipeline – Filed 60

8.3 R&D Pipeline – Phase III 60

8.4 R&D Pipeline – Phase II 62

8.5 R&D Pipeline – Phase I 62

8.6 R&D Pipeline – Pre-clinical 63

8.7 R&D Pipeline – Discovery 65

8.8 R&D Pipeline – IND Filed 66

9 Biosimilars in Emerging Economies – Industry Dynamics 69

9.1 Strategies Adopted By Branded Biologic Companies to Beat Generic Competition 69

9.1.1 Introduction 69

9.1.2 Second Generation Biologics 70

9.1.3 New Formulation 70

9.1.4 Combination Products 70

9.1.5 New Approved Indications 71

9.2 Industry Dynamics: Strategies to Be Adopted by Companies to Enter the Biosimilars Market 71

9.2.1 Product 72

9.2.2 Price 72

9.2.3 Place 72

9.2.4 Promotion 73

9.2.5 People 73

10 Biosimilars in Emerging Economies – Deals Analysis 74

4 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,094.22 +56.25 0.31%
S&P 500 2,112.43 +3.51 0.17%
NASDAQ 5,064.9490 +4.7030 0.09%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs